DiaMedica's Preeclampsia Drug Shows Strong Blood Pressure Reductions in Phase 2
DMAC sits 50% above its 52-week low of $4.39.
Summary
DiaMedica reported Q2 2026 financials alongside significant clinical progress. The Phase 2 Part 1a preeclampsia trial showed DM199 produced a mean 29.1 mmHg systolic blood pressure reduction in the highest-dose cohorts, with sustained effects over 24 hours. This is the first detailed efficacy data from the program and supports moving into early-onset preeclampsia studies. The company also completed the first FGR cohort and surpassed 85% enrollment in the pivotal ReMEDy2 stroke trial, with interim analysis expected in early 2027. Health Canada authorized the early-onset PE study, with first patient dosing planned for Q4 2026. These updates follow a Q1 marked by trial delays and increased cash burn, making the positive data a potential turning point. The conference call tomorrow morning will provide financial details and further commentary.
Updates
· SEC 10-Q — Q2 net loss was $10.1 million, or $0.19 per share, with R&D expenses of $8.2 million. Cash and marketable securities totaled $43.5 million as of June 30, 2026.
At the time of this announcement, DMAC was trading at $6.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $358.3M. The 52-week trading range was $4.39 to $10.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.